Literature DB >> 33591947

Blockade of Indoleamine 2, 3-dioxygenase 1 ameliorates hippocampal neurogenesis and BOLD-fMRI signals in chronic stress precipitated depression.

Lei Gao1, Tingting Gao1, Ting Zeng1, Peng Huang1,2, Nai-Kei Wong3, Zhaoyang Dong4, Yunjia Li1, Guanghui Deng1, Zhiyong Wu1, Zhiping Lv1.   

Abstract

Indoleamine 2, 3-dioxygenase 1 (IDO1) has been implicated in the pathogenesis of depression, though its molecular mechanism is still poorly understood. We investigated the molecular mechanism of IDO1 in depression by using the chronic unpredictable mild stress (CUMS) model in Ido1-/- mice and WT mice. The brain blood oxygen level dependent (BOLD) signals in mice were collected by functional magnetic resonance imaging (fMRI) technology. IDO1 inhibitor INCB024360 was intervened in dorsal raphe nucleus (DRN) through stereotactic injection. We found an elevation of serum IDO1 activity and decreased 5-HT in CUMS mice, and the serum IDO1 activity was negatively correlated with 5-HT level. Consistently, IDO1 was increased in hippocampus and DRN regions, accompanied by a reduction of hippocampal BDNF levels in mice with CUMS. Specifically, pharmacological inhibition of IDO1 activity in the DRN alleviated depressive-like behaviour with improving hippocampal BDNF expression and neurogenesis in CUMS mice. Furthermore, ablation of Ido1 exerted stress resistance and decreased the sensitivity of depression in CUMS mice with the stable BOLD signals, BDNF expression and neurogenesis in hippocampus. Thus, IDO1 hyperactivity played crucial roles in modulating 5-HT metabolism and BDNF function thereby impacting outcomes of hippocampal neurogenesis and BOLD signals in depressive disorder.

Entities:  

Keywords:  IDO1; blood oxygen level-dependent signal; depression; dorsal raphe nucleus; neurogenesis

Mesh:

Substances:

Year:  2021        PMID: 33591947      PMCID: PMC7950278          DOI: 10.18632/aging.202511

Source DB:  PubMed          Journal:  Aging (Albany NY)        ISSN: 1945-4589            Impact factor:   5.682


  44 in total

Review 1.  Depression.

Authors:  Gin S Malhi; J John Mann
Journal:  Lancet       Date:  2018-11-02       Impact factor: 79.321

2.  Voluntary wheel running ameliorates depression-like behaviors and brain blood oxygen level-dependent signals in chronic unpredictable mild stress mice.

Authors:  Peng Huang; Zhaoyang Dong; Weiliang Huang; Chuying Zhou; Weichao Zhong; Peiqian Hu; Ge Wen; Xuegang Sun; Heyu Hua; Huihui Cao; Lei Gao; Zhiping Lv
Journal:  Behav Brain Res       Date:  2017-05-17       Impact factor: 3.332

Review 3.  Emerging antidepressants to treat major depressive disorder.

Authors:  Samantha G Block; Charles B Nemeroff
Journal:  Asian J Psychiatr       Date:  2014-09-16

4.  Fibroblast Growth Factor 2 Modulates Hypothalamic Pituitary Axis Activity and Anxiety Behavior Through Glucocorticoid Receptors.

Authors:  Natalina Salmaso; Hanna E Stevens; Jessica McNeill; Maha ElSayed; Qiuyin Ren; Maria E Maragnoli; Michael L Schwartz; Simone Tomasi; Robert M Sapolsky; Ronald Duman; Flora M Vaccarino
Journal:  Biol Psychiatry       Date:  2016-03-02       Impact factor: 13.382

Review 5.  From inflammation to sickness and depression: when the immune system subjugates the brain.

Authors:  Robert Dantzer; Jason C O'Connor; Gregory G Freund; Rodney W Johnson; Keith W Kelley
Journal:  Nat Rev Neurosci       Date:  2008-01       Impact factor: 34.870

6.  Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease.

Authors:  M P Heyes; K Saito; J S Crowley; L E Davis; M A Demitrack; M Der; L A Dilling; J Elia; M J Kruesi; A Lackner
Journal:  Brain       Date:  1992-10       Impact factor: 13.501

7.  Convergent effects of mouse Pet-1 deletion and human PET-1 variation on amygdala fear and threat processing.

Authors:  Cara L Wellman; Marguerite Camp; V Morgan Jones; Kathryn P MacPherson; Jessica Ihne; Paul Fitzgerald; Mouna Maroun; Emily Drabant; Ryan Bogdan; Ahmad R Hariri; Andrew Holmes
Journal:  Exp Neurol       Date:  2013-10-04       Impact factor: 5.330

Review 8.  Epigenetic and epistatic interactions between serotonin transporter and brain-derived neurotrophic factor genetic polymorphism: insights in depression.

Authors:  Z M Ignácio; G Z Réus; H M Abelaira; J Quevedo
Journal:  Neuroscience       Date:  2014-06-24       Impact factor: 3.590

9.  Central Nervous System Infection with Borna Disease Virus Causes Kynurenine Pathway Dysregulation and Neurotoxic Quinolinic Acid Production.

Authors:  Simone Formisano; Mady Hornig; Kavitha Yaddanapudi; Mansi Vasishtha; Loren H Parsons; Thomas Briese; W Ian Lipkin; Brent L Williams
Journal:  J Virol       Date:  2017-06-26       Impact factor: 5.103

10.  Resting State Functional Connectivity of Dorsal Raphe Nucleus and Ventral Tegmental Area in Medication-Free Young Adults With Major Depression.

Authors:  Amit Anand; Stephen E Jones; Mark Lowe; Harish Karne; Parashar Koirala
Journal:  Front Psychiatry       Date:  2019-01-25       Impact factor: 4.157

View more
  4 in total

1.  Identifying Antidepressant Effects of Brain-Derived Neurotrophic Factor and IDO1 in the Mouse Model Based on RNA-Seq Data.

Authors:  Jing Ren; Chenyang Li; Songren Wei; Yanjun He; Peng Huang; Jiangping Xu
Journal:  Front Genet       Date:  2022-05-30       Impact factor: 4.772

2.  MiR-139-5p has an antidepressant-like effect by targeting phosphodiesterase 4D to activate the cAMP/PKA/CREB signaling pathway.

Authors:  Peng Huang; Songren Wei; Meng Luo; Zhuohong Tang; Qingmei Lin; Xing Wang; Mi Luo; Yanjun He; Chuan Wang; Dezhan Wei; Chenglai Xia; Jiangping Xu
Journal:  Ann Transl Med       Date:  2021-10

Review 3.  Imaging and spectroscopic methods to investigate adult neurogenesis in vivo: New models and new avenues.

Authors:  Nathalie Just; Pierre-Marie Chevillard; Martine Migaud
Journal:  Front Neurosci       Date:  2022-08-05       Impact factor: 5.152

Review 4.  Tryptophan Metabolism in Depression: A Narrative Review with a Focus on Serotonin and Kynurenine Pathways.

Authors:  Ana Salomé Correia; Nuno Vale
Journal:  Int J Mol Sci       Date:  2022-07-31       Impact factor: 6.208

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.